These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 19642171)

  • 1. Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage.
    Buitrago-Molina LE; Pothiraju D; Lamlé J; Marhenke S; Kossatz U; Breuhahn K; Manns MP; Malek N; Vogel A
    Hepatology; 2009 Aug; 50(2):500-9. PubMed ID: 19642171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
    Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
    Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.
    Beuvink I; Boulay A; Fumagalli S; Zilbermann F; Ruetz S; O'Reilly T; Natt F; Hall J; Lane HA; Thomas G
    Cell; 2005 Mar; 120(6):747-59. PubMed ID: 15797377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin.
    Huang S; Liu LN; Hosoi H; Dilling MB; Shikata T; Houghton PJ
    Cancer Res; 2001 Apr; 61(8):3373-81. PubMed ID: 11309295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
    Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
    Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells.
    Metcalfe SM; Canman CE; Milner J; Morris RE; Goldman S; Kastan MB
    Oncogene; 1997 Oct; 15(14):1635-42. PubMed ID: 9349496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Pathways Leading to Induction of Cell Death and Anti-Proliferative Properties by Tacrolimus and mTOR Inhibitors in Liver Cancer Cells.
    Navarro-Villarán E; de la Cruz-Ojeda P; Contreras L; González R; Negrete M; Rodríguez-Hernández MA; Marín-Gómez LM; Álamo-Martínez JM; Calvo A; Gómez-Bravo MA; de la Cruz J; Padillo J; Muntané J
    Cell Physiol Biochem; 2020 May; 54(3):457-473. PubMed ID: 32369692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAD001 enhances the radiosensitivity of SCC4 oral cancer cells by inducing cell cycle arrest at the G2/M checkpoint.
    Yu CC; Hung SK; Liao HF; Lee CC; Lin HY; Lai HC; Li SC; Ho HC; Huang HB; Su YC
    Anticancer Res; 2014 Jun; 34(6):2927-35. PubMed ID: 24922656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAD001 (everolimus) induces dose-dependent changes to cell cycle regulation and modifies the cell cycle response to vincristine.
    Saunders PO; Weiss J; Welschinger R; Baraz R; Bradstock KF; Bendall LJ
    Oncogene; 2013 Oct; 32(40):4789-97. PubMed ID: 23128395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells.
    Zitzmann K; De Toni EN; Brand S; Göke B; Meinecke J; Spöttl G; Meyer HH; Auernhammer CJ
    Neuroendocrinology; 2007; 85(1):54-60. PubMed ID: 17310129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
    Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
    Grozinsky-Glasberg S; Rubinfeld H; Nordenberg Y; Gorshtein A; Praiss M; Kendler E; Feinmesser R; Grossman AB; Shimon I
    Mol Cell Endocrinol; 2010 Feb; 315(1-2):87-94. PubMed ID: 19815051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo and in vitro effects of RAD001 on bladder cancer.
    Vasconcelos-Nóbrega C; Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Brochado P; Cardoso ML; Palmeira C; Salvador A; Guedes-Teixeira CI; Colaço A; Palomino LF; Lopes C; Santos L; Oliveira PA
    Urol Oncol; 2013 Oct; 31(7):1212-21. PubMed ID: 22169072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAD001 (Everolimus) Can prevent tamoxifen-related endometrial and stromal hyperplasia.
    Erdemoglu E; Güney M; Take G; Giray SG; Mungan T
    Int J Gynecol Cancer; 2009 Apr; 19(3):375-9. PubMed ID: 19407562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.
    Hosoi H; Dilling MB; Shikata T; Liu LN; Shu L; Ashmun RA; Germain GS; Abraham RT; Houghton PJ
    Cancer Res; 1999 Feb; 59(4):886-94. PubMed ID: 10029080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
    Boulay A; Rudloff J; Ye J; Zumstein-Mecker S; O'Reilly T; Evans DB; Chen S; Lane HA
    Clin Cancer Res; 2005 Jul; 11(14):5319-28. PubMed ID: 16033851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D(3) to induce growth arrest and differentiation of AML cells in vitro and in vivo.
    Yang J; Ikezoe T; Nishioka C; Ni L; Koeffler HP; Yokoyama A
    Exp Hematol; 2010 Aug; 38(8):666-76. PubMed ID: 20382200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo.
    Kwon YS; Hong HS; Kim JC; Shin JS; Son Y
    Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):454-60. PubMed ID: 15671269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel role of the CXC chemokine receptor 3 in inflammatory response to arterial injury: involvement of mTORC1.
    Schwarz JB; Langwieser N; Langwieser NN; Bek MJ; Seidl S; Eckstein HH; Lu B; Schömig A; Pavenstädt H; Zohlnhöfer D
    Circ Res; 2009 Jan; 104(2):189-200. PubMed ID: 19059841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.